The cancer stem cell hypothesis posits that malignant growth arises from a rare population of progenitor cells within a tumor that provide it with unlimited regenerative capacity. Such cells also possess increased resistance to chemotherapeutic agents. Resurgence of chemoresistant disease after primary therapy typifies epithelial ovarian cancer and may be attributable to residual cancer stem cells, or cancer-initiating cells, that survive initial treatment. As the cell surface marker CD133 identifies cancerinitiating cells in a number of other malignancies, we sought to determine the potential role of CD133 þ cells in epithelial ovarian cancer. We detected CD133 on ovarian cancer cell lines, in primary cancers and on purified epithelial cells from ascitic fluid of ovarian cancer patients. We found CD133 þ ovarian cancer cells generate both CD133 þ and CD133À daughter cells, whereas CD133À cells divide symmetrically. CD133 þ cells exhibit enhanced resistance to platinum-based therapy, drugs commonly used as first-line agents for the treatment of ovarian cancer. Sorted CD133 þ ovarian cancer cells also form more aggressive tumor xenografts at a lower inoculum than their CD133À progeny. Epigenetic changes may be integral to the behavior of cancer progenitor cells and their progeny. In this regard, we found that CD133 transcription is controlled by both histone modifications and promoter methylation. Sorted CD133À ovarian cancer cells treated with DNA methyltransferase and histone deacetylase inhibitors show a synergistic increase in cell surface CD133 expression. Moreover, DNA methylation at the ovarian tissue active P2 promoter is inversely correlated with CD133 transcription. We also found that promoter methylation increases in CD133À progeny of CD133 þ cells, with CD133 þ cells retaining a less methylated or unmethylated state. Taken together, our results show that CD133 expression in ovarian cancer is directly regulated by epigenetic modifications and support the idea that CD133
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Introduction
Epithelial ovarian cancer is the most lethal gynecologic malignancy with the majority of cases being diagnosed after the disease has become metastatic. Five-year survival is about 40%. Despite responsiveness to primary therapy, the majority of these malignancies recur because of the selection or acquisition of chemoresistance by residual cells. Cancer-initiating cells are thought to constitute a small subset of cells within a tumor that both initiate the primary disease and its recurrence because of their capacity for self-renewal and inherent chemoresistance. Cancer stem cells have been identified in a growing number of hematopoietic and solid tissue malignancies and are typically recognized by virtue of the expression of cell surface markers. The pentaspan transmembrane glycoprotein CD133, also known as Prominin-1, was originally described as a hematopoietic stem cell marker (Yin et al., 1997) and was subsequently shown to be expressed by a number of progenitor cells including those of the epithelium, where it is expressed on the apical surface (Corbeil et al., 2000) . CD133 expression distinguishes a number of cancer-initiating cells, including those associated with brain (Singh et al., 2004; Liu et al., 2006) , pancreatic (Olempska et al., 2007) , liver (Ma et al., 2002; Yin et al., 2007) , skin (Monzani et al., 2007) , prostate (Collins et al., 2005; Miki et al., 2007) and colon cancers (O'Brien et al., 2007; Ricci-Vitiani et al., 2007) .
Recent studies have substantiated that ovarian cancer may arise from aberrant stem cells. Several groups have shown that epithelial ovarian cancer initiates from the clonal expansion of a single progenitor cell (Jacobs et al., 1992; Mok et al., 1992) . More recently, Szotek et al. (2006) have demonstrated that a subpopulation of cells isolated from ovarian cancer cell lines and ascitic fluid of ovarian cancer patients phenotypically resembles cancer stem cells. In addition, Ferrandina et al. (2007) used flow cytometry to find that CD133 þ cells were more frequently detected in primary ovarian cancers than in their metastatic omental lesions or in normal ovaries. In addition, these studies strongly implicate cancer stem cells in the etiology of ovarian cancer and suggest that CD133 þ cells are involved in this process. To further our understanding of the potential role of CD133 þ cells in ovarian cancer, we examined CD133 expression in ovarian cancer cell lines and in primary ovarian cancer specimens, and performed in vitro and in vivo studies, including tumor xenograft experiments, of isolated CD133 þ and CD133À ovarian cancer cells. We also undertook investigation of the potential epigenetic regulation of CD133, both in established ovarian cell lines and in primary ovarian cancer tissues.
Results and discussion

CD133 is expressed by many ovarian cancer cell lines
We used flow cytometry with a monoclonal anti-CD133 antibody to analyse 42 established ovarian cell lines, including 40 malignant and two spontaneously immortalized normal ovarian surface epithelium cell lines (Supplementary Table S1 ) for cell surface expression of the CD133 antigen. The antibody we used is specific for the AC133 epitope of CD133 that is present on progenitor cells (Mizrak et al., 2008) . Of 40 malignant lines, 15 (37.5%) were positive for CD133 expression (representative results shown in Figure 1a ; also see Supplementary Figure S1 ) and two immortalized normal ovarian surface epithelium cell lines were negative for CD133 expression (data not shown). Cell surface expression of CD133 protein, on the basis of the percentage of CD133 positivity measured by flow cytometry, correlated with (Szotek et al., 2006) . Perhaps, the heterogeneous CD133 þ /À cell lines are those that have somehow retained the ability to undergo asymmetric division.
CD133 þ ovarian cancer cells produce CD133 þ and CD133À progeny Five cell lines (A2780, PEO1, OVCA432, OVCAR-2 and OV90) contained both CD133 þ and CD133À populations ( Figure 1a and Supplementary Figure S1 ). We surmised that either the CD133 þ and CD133À cells were from different lineages and have coexisted in the same cultured cell milieu over many generations or that one population was giving rise to the other. To distinguish these alternatives, we sorted the A2780 and PEO1 cell lines on the basis of CD133 surface expression and plated representative positive and negative cells at single cell dilution. Microscopic visualization confirmed the presence of one cell per well of the 96-well culture plates. Expanded cultures from these single cell isolates were then analysed using flow cytometry to determine the proportions of CD133 þ and CD133À cells present in each clonal expansion. We found that growth of a single PEO1 or A2780 CD133À cell led to the production of more CD133À progeny ( Figure 1a and Supplementary Figure S2 ). In contrast, CD133 þ A2780 or PEO1 cells either produced more CD133 þ cell populations or produced heterogeneous cell populations, indicating they are capable of producing progeny of two phenotypes and thus may undergo asymmetric cell division, a characteristic of progenitor cells.
Ascitic fluid and tumors from ovarian cancer patients contain CD133 þ cancer cells We next examined advanced stage primary ovarian cancer tissues by immunohistochemistry to determine whether CD133 þ cells were present. As a positive control, we examined a 54-day gestation gut tissue and detected CD133 at apical edges of cells in the lumens as described earlier (Corbeil et al., 2000) ( Figure 2a ). We observed clear staining above background in 10 of 32 primary serous epithelial ovarian cancers that was present at variable intensity and primarily at the luminal edges of glandular structures ( Figure 2a and Supplementary Figure S3 ). Similar to the ovarian cancer cell lines, tumors that exhibited positive staining for CD133 also exhibited higher levels of CD133 mRNA (Mann-Whitney test, P ¼ 0.0005; Figure 2b ). Furthermore, three of seven purified tumor epithelial cells derived from ascitic fluid of patients with primary epithelial ovarian cancer (Hurteau et al., 1994) showed cell surface expression of CD133 by immunohistochemistry (two shown in Figure 2c ). We examined 12 additional ascitic fluid specimens using flow cytometry to determine the proportion of CD133 þ cells present. Identification was based on two-color flow cytometry with CD133-PE and CD45-FITC antibodies. CD133 þ cells were present in five (42%) specimens and comprised from 0.93 to 15% of the CD45(À) cells in the population (Figure 2c and Supplementary Figure S4 ). The presence of CD133 þ cells in both the primary solid tumors and the ascitic fluid specimens indicates that these cells may be present early in tumor development and capable of acquiring metastatic potential.
Heightened aggressiveness of CD133 þ ovarian cancer cell xenografts One of the defining characteristics of cancer-initiating cells is their enhanced ability to form xenograft tumors versus cells derived from the bulk tumor population. We therefore performed tumor xenograft experiments by injecting 4-to 5-week-old BALB/cAnNCr-nu/nu mice with 10 3 (N ¼ 5), 10 4 (N ¼ 10) and 10 5 (N ¼ 7)-sorted CD133À (left flank) and CD133 þ (right flank) A2780 cells. In each case, CD133 þ cells formed tumors that grew to a larger size and appeared with shorter latency than tumors from CD133À cells isolated from the same parental cell line (Figures 3a-c) . There was a significant difference in tumor volume for the groups receiving 10 3 (P ¼ 0.015; 28 days) and 10 4 injected cells (P ¼ 0.016; 20 days), but not for the group receiving 10 5 injected cells (P ¼ 0.313; 20 days).
Xenograft tumors derived from both CD133 þ and CD133À A2780 cells were poorly differentiated, with no substantive qualitative differences (Figure 3d and data not shown). Immunohistochemical staining of these xenografts revealed that the tumors derived from CD133 þ cells contained areas of positive and negative staining for CD133. This pattern is suggestive that CD133 þ cells within the homogeneous inocula underwent asymmetric division during tumor growth. CD133 was not detected, or detected at extremely low frequency, in xenografts formed from the CD133À cells (Figure 3d ). The CD133 þ cells in the CD133À cell-derived tumors were either present as isolated cells or more frequently as small clusters of cells, as shown for in Figure 3d . It is plausible that residual CD133 þ cells were present in the CD133À inocula after sorting, and this small fraction of cells was responsible for the observed tumor growth. Regardless, although both CD133 þ and CD133À A2780 cells formed xenograft tumors, the CD133 þ cells are more efficient in this process.
Increased cisplatin resistance in CD133 þ ovarian cancer cells Cancer stem cells, including those that are CD133 þ , may possess inherent resistance to chemotherapeutic CD133 þ cells in ovarian cancer T Baba et al agents (Frank et al., 2005; Lobo et al., 2007) . Platinum drugs are commonly used as first-line therapeutic agents in treating ovarian cancer. We therefore determined cisplatin IC 50 values for sorted CD133 þ and CD133À ovarian cancer cells. We found that CD133 þ cells were more resistant to cisplatin than CD133À cells (P ¼ 0.009 and 0.0001 for A2780 and PEO1, respectively; paired t-test, Supplementary Figure S5 ). In addition, expression CD133 þ cells in ovarian cancer T Baba et al levels of CD133 mRNA by microarray were significantly correlated with chemoresistance to cisplatin in CD133 þ cell lines (r 2 ¼ 0.64, P ¼ 0.002; data not shown). Our data thus far support that CD133 þ A2780 and PEO1 ovarian cancer cells possess many of the characteristics of cancer-initiating cells as reported earlier in cancer cell lines derived from other tissues (Ma et al., 2002; Monzani et al., 2007; Shiras et al., 2007) .
Sorted CD133 þ cells and their CD133À progeny exhibit divergent gene expression profiles Variation in CD133 cell surface expression in the ovarian cancer cells may reflect generalized gene expression profiles that are associated with different phenotypes. Microarray analysis of the sorted A2780 and PEO1 CD133 þ and CD133À cells supports that these cell populations exhibit significantly different gene expression profiles, consistent with the idea that the CD133 þ cells can give rise to phenotypically distinct progeny. Using GATHER (Chang and Nevins, 2006) , upregulated genes in sorted CD133 þ cells were associated with Gene Ontology (GO) terms including 'antiapoptotic' or 'regulation of apoptosis' as well as 'development' and 'morphogenesis.' Genes downregulated in the CD133 þ cells included those associated with GO terms for 'negative regulation of cell growth' or 'negative regulation of development' in addition to 'induction of apoptosis through death domain receptors' (Supplementary Tables S2-S5 ). Positive CD133 status may therefore reflect the capacity of cells to undergo asymmetric division and resist apoptotic signaling.
CD133 positivity in ovarian cancer cells is associated with a distinct gene expression signature shared with other cancer-initiating cells We used binary regression on the basis of CD133 cell surface expression in the ovarian cancer cell lines to develop a gene signature that is associated with CD133 positivity (Supplementary Figure S6a) . This collective gene profile (Supplementary Table S6 ) accurately classified 37 of 42 advanced stage (III/IV) serous epithelial ovarian cancers from our previously published microarray data set (Berchuck et al., 2005) as CD133 þ or CD133À using leave-one-out cross-validation (88% accuracy; Supplementary Figures S6b) . The probability of the ovarian cancers possessing this CD133 gene signature was also positively correlated with the expression of CD133 (P ¼ 0.04; data not shown). The CD133 signature probability was higher in undifferentiated cells than their differentiated counterparts from publicly available gene sets (NCBI Gene Expression Omnibus; Barrett et al., 2007) , including primary glioma CD133 þ cells versus CD133À cells (GSE7181; P ¼ 0.03, paired t-test) (Beier et al., 2007) and glioblastoma-initiating cells in stem cell selection media versus primary glioblastoma cells in non-selective media (GSE4536; Po0.0001, Mann-Whitney test) (Lee et al., 2006) (Supplementary Figure S6c) . These results suggest that there are common gene expression profiles among cancer-initiating cells regardless of tissue of origin.
CD133 expression is regulated by DNA methylation and histone modifications Recent studies have implicated epigenetic alterations, including DNA methylation and histone modifications, as prominent factors that contribute to the phenotype of cancer progenitor cells (Jones and Baylin, 2007; Liu et al., 2007; Widschwendter et al., 2007) . CD133 was previously characterized as having five alternative promoters (P1-P5) that are active in a tissue-dependent manner (Shmelkov et al., 2004) . The P1, P2 and P3 promoters are located within a 1540-bp CpG island (17.4% CpG, observed to expected CpG ratio ¼ 0.82), whereas promoters P4 and P5 are not encompassed by CpG-rich sequences. Using an in vitro reporter system, Shmelkov and colleagues determined that P1 and P2, whose exon 1A-specific and exon 1B-specific exons, respectively, are located 244 bp apart, are inactive when methylated, suggesting that they may be epigenetically regulated. Because CD133 promoter 2 is the only active promoter in ovarian tissues (Shmelkov et al., 2004) , and CD133 expression in our ovarian cancer cell lines was highly variable, we investigated the possibility that this variability is due to promoter methylation. Of the 40 ovarian cancer cell lines treated for 72 h with the DNA methyltransferase inhibitor, decitabine, 27 exhibited an increase in CD133 mRNA levels (P ¼ 0.01, two-tailed paired t-test; Supplementary Figure S7) . Generally, cells with very high endogenous CD133 levels exhibited modest decreases in CD133 expression resulting from decitabine treatment, whereas those with low CD133 expression exhibited modest to substantial increases in CD133 transcripts. These results indicate that CD133 is either directly or indirectly epigenetically regulated.
We examined the methylation status of 15 CpG cytosines using bisulfite sequencing to assess the possibility of a direct epigenetic influence on CD133 expression. These CpG sites are located from À366 to À191 bp 5 0 of P2 promoter-specific exon 1B and 
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T Baba et al partially overlap (13 of 15 CpGs) with the region tested for influence of methylation on transcription in vitro (Shmelkov et al., 2004) . As shown in Figures 4a and b , 34 cell lines exhibited complete or partial methylation of cytosines in this region. Consistent with this finding, the levels of CD133 mRNA and the degree of methylation present at the P2 promoter region are inversely correlated in the ovarian cell lines (Spearman r ¼ À0.63; 95% CI: À0.79 to À0.37; Po0.0001; Figure 4b ). IGROV1, which is universally CD133À, showed 98% average methylation for this region, whereas CD133 þ OVCAR-8 was completely (0%) unmethylated (representative sequences shown in Figure 4a ). A2780 and PEO1 parental (unselected) cells exhibit 47 and 38% methylation, respectively. Two spontaneously immortalized normal ovarian surface epithelium cell lines had an average of 77 and 79% methylation for this region (data not shown). The P2 promoter region was variably methylated in primary cancers and methylation in these tissues was inversely associated with the level of expression of CD133 (Figure 4a ), although these particular results should be regarded as preliminary because of the small sample size. Intriguingly, daughter CD133À cells from the PEO1 and A2780 cell lines exhibited increased methylation relative to the parental CD133 þ cells (representative sequences shown in Figure 4c ).
Treatment of sorted CD133À cells with decitabine or trichostatin A, a histone deacetylase inhibitor, led to an increase in cell surface expression of CD133 in the selected CD133À cells, and combined drug treatment was synergistic for increasing cell surface CD133 (Figure 4d ). These results are suggestive that histone modifications may also be involved in the epigenetic regulation of CD133 and are consistent with the activation of pluripotency-associated genes, including CD133, observed in mouse neurosphere cells with combined decitabine and trichostatin A treatment (Ruau et al., 2008) . Together, our data support a causal link between DNA methylation and the silencing of CD133 expression and suggest that histone deacetylation may contribute to epigenetic regulation of the CD133 P2 promoter. 
Concluding remarks
The existence of ovarian cancer-initiating cells was previously supported by others in studies whereby cancer cells isolated from ascitic fluid of ovarian cancer patients exhibited characteristics consistent with those expected of a cancer stem cell (Bapat et al., 2005; Szotek et al., 2006) . More recently, CD44 þ ovarian cancer cells have been shown to possess cancer-initiating capabilities (Zhang et al., 2008) . However, CD133 expression was not examined in these studies, so the potential overlap (as reported for prostate cancer; Collins et al., 2005; Maitland and Collins, 2008) , or independence (as reported for breast cancer; Wright et al., 2008) , of CD44 þ and CD133 þ cells in ovarian malignancies remains unclear. Our results extend more recent findings that CD133 þ cells are present in epithelial ovarian cancers (Ferrandina et al., 2007) and together with our functional studies provide support for the idea that ovarian cancer CD133 þ subpopulations possess ovarian cancer-initiating cell characteristics.
The increased chemoresistance of CD133 þ cells may allow survival through primary therapy and afford these cells the opportunity to cause disease recurrence, a major problem in treating patients with ovarian cancer. Acquisition of CD133 promoter methylation in CD133À cells that result from CD133 þ cell division and the inverse correlation between CD133 transcription and methylation provide a plausible mechanistic explanation for the loss of cell surface CD133 expression in differentiated cells. This is consistent with the notion that cell differentiation is accompanied by epigenetic changes that are responsible for guiding the future phenotypic profile of the progeny (Gan et al., 2007) . This phenomenon is not unique to normal stem cells but also may be present aberrantly in cancer stem cells, perhaps having initiated carcinogenesis (Balch et al., 2007; Ohm et al., 2007) . Methylation of the CD133 promoter may be generally representative of epigenetic repression of other pluripotency-associated genes (Ruau et al., 2008) . The methylation status of CD133 may therefore be useful as one component of a biomarker panel to determine the activity of this group of genes within a tumor, and this in turn could provide important and relevant information with regard to patient care and prognosis. The function of CD133 is currently unknown, but our finding that CD133 expression is repressed concomitant with the acquisition of DNA methylation in CD133À progeny of CD133 þ cells supports a role for CD133 in the CD133 þ cells, which is not required in the CD133À cells after asymmetric division. Our results underscore an important need for further evaluation of CD133 and other stem cell markers in ovarian malignancies and investigation of how these cells can be targeted by novel treatment modalities that might lead to more effective eradication of ovarian cancer following diagnosis and prevention of disease relapse.
Materials and methods
Cultured cells and tissues
Cells were maintained in RPMI 1640 medium with L-glutamine (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (Mediatech; Herndon, VA, USA). Normal and malignant ovarian tissues and ascitic fluid specimens were obtained with informed consent and provided by the Duke University Gynecologic Oncology Tumor Bank. Human conceptal tissue was obtained from the NIH-supported Birth Defects Research Laboratory at the University of Washington. All human tissues were used under a research protocol approved by the Duke University Institutional Review Board.
Flow cytometry
Ascitic fluid cell pellets from 12 ovarian cancer patients were examined by flow cytometry. The pellets were stored at À80 1C in fetal bovine serum with 10% DMSO. The cell pellets were thawed, underwent red blood cell lysis, and were centrifuged and resuspended in fresh RPMI 1640 media. The cells were counted to obtain a cell concentration of less than 1 Â 10 7 cells per ml for flow cytometry staining. Cells were centrifuged and resuspended in FcR Blocking Reagent (Miltenyi Biotec, Auburn, CA, USA) in a 1:5 ratio with 0.5% bovine serum albumin (Sigma, St Louis, MO, USA) in 0.05% sodium azide (Ricca Chemicals, Arlington, TX, USA) in phosphate-buffered saline. Cultured cell lines were trypsinized and resuspended in this blocking reagent. Mouse anti-human CD133/1-PE or CD45-FITC monoclonal antibodies were then added (1:11 dilution) and incubated for 30 min at 4 1C in the dark. Isotype controls were also used, including mouse IgG1-PE and mouse IgG2-FITC (antibodies from Miltenyi Biotec). After two cycles of washing, the cells were formalin fixed. The cells were transferred through a 35-nm nylon mesh into polystyrene tubes and stored at 4 1C in the dark until processing. Flow cytometric data were obtained for analysis of more than 1 Â 10 4 cells for each sample on a FACScan instrument (BD Biosciences, San Jose, CA, USA) at the Duke Comprehensive Cancer Center Flow Cytometry Shared Resource Facility (FCSR).
Flow-activated cell sorting was performed using 2 Â 10 6 cells for each sample. Cells were resuspended in 5 ml of RPMI 1640 with 2% fetal bovine serum, stained with CD133/1-APC antibody (1:20 dilution, Miltenyi Biotech, Auburn, CA) for 30 min on ice and prepared for sorting as described earlier . Single CD133 þ or CD133À cells were sorted on the basis of CD133 positivity and then independently seeded into 96-well plates by FACS Advantage SE (BD Biosciences) at the FCSR. Visual inspection was performed the day after the initial plating to confirm that each contained a single cell. After 3 weeks of growth, 8 and 12 clones were obtained, which were derived from a single CD133 þ or CD133À parent cell, respectively. Multicell sorting was performed to obtain the proportions of CD133 þ and CD133À cells in each population.
Immunohistochemical staining
Tissue, cells and human conceptal gut were formalin-fixed and paraffin-embedded followed by sectioning (5 mm) onto slides. Cytospin preparations of cells from ascitic fluid of seven ovarian cancer patients were prepared from frozen aliquots after selection and confirmation of the epithelial fraction as described earlier (Hurteau et al., 1994) . Ovarian cancer tissue microarrays were prepared using triplicate 1-mm cores of 30 advanced-stage serous epithelial ovarian cancers from the Duke Gynecologic Oncology Tumor Bank. Two additional specimens were stained from standard 5 mm sections prepared from paraffin-embedded tissues. Primary ovarian cancer specimens used in this study were derived from a previously described data set (Berchuck et al., 2005) . Before tissue microarray preparation, hematoxylin and eosin sections from CD133 þ cells in ovarian cancer T Baba et al each donor block were examined by a board-certified pathologist for tumor content and marked for core selection. AE 1 /AE 3 cytokeratin staining (Dako, Glostrup, Denmark) of 5 mm sections of the tissue microarray was used to confirm epithelial content. Antigen retrieval was performed in a Decloaking Chamber (Biocare Medical, Concord, CA, USA) using a citrate buffer. An endogenous peroxidase block was followed by nonspecific background blocking and incubation with a 1:10 dilution of CD133/1 (AC133) pure (Miltenyi Biotech) or mouse IgG1 (Biogenex, San Ramon, CA, USA). A 1:1000 dilution of CD133/1 was used for frozen cytospin specimens. Slides were stained with DAB chromagen and counterstained with methyl green. AE 1 /AE 3 cytokeratin (Dako) staining at a 1:4 dilution confirmed the epithelial cell purity of the ascitic cytospins.
CD133 expression in 5 mm serial sections from paraffinembedded mouse A2780 ovarian cancer cell xenograft tumors was confirmed using a rabbit anti-human CD133 antibody (C24B9; 1:200 dilution; Cell Signaling Technology Inc., Danvers, MA, USA) and a rabbit IgG1 negative control (Biogenex). Sections were examined and documented microscopically using an Olympus Vanox-S equipped with an Olympus DP11 camera.
Xenograft tumors BALB/cAnNCr-nu/nu female mice (4-to 5-week-old) were obtained from NCI-Frederick (Frederick, MD, USA) and maintained within facilities operated by the Duke University and Medical Center Animal Care and Use Program. Mice were provided with water and food ad libitum and were housed at p5 animals per cage. Animal studies were approved by, and performed in accordance with, the Duke University Institu- , N ¼ 10 or 1 Â 10 5 , N ¼ 7) sorted from A2780 cells were suspended in a 1:1 mixture of media and matrigel (BD Biosciences) and inoculated subcutaneously into the right and left flanks, respectively, as described earlier (Ma et al., 2007a; O'Brien et al., 2007) . Tumor volume was assessed using a digital caliper and determined with the formula: tumor volume (mm 3 ) ¼ length (mm) Â 2 (width (mm)) Â 0.52.
Epigenetic analyses
To analyse CD133 P2 promoter methylation, genomic DNA was treated with sodium bisulfite as described earlier (Huang et al., 2006) . PCR primers (forward: 5 0 -GGTTGAGTAGGT ATTTTTATAGGAAATGG-3 0 and reverse: 5 0 -CTCCTACTC CCRCCCTAATCAC-3 0 ) produced 482-bp amplicons, which were resolved on 2% agarose gels, purified using Sigma GenElute gel purification columns (Sigma-Aldrich, St Louis, MO, USA) and sequenced using the ThermoSequenase Radiolabeled Terminator Cycle Sequencing Kit (USB Corporation, Cleveland, OH, USA) with primer 5 0 -GGAAATGG ATGTTGTTTAGGTGTTG-3 0 . Sequencing products were resolved on acrylamide sequencing gels, dried and exposed to a phosphor screen prior to phosphorimaging using the Molecular Dynamics and ImageQuant software are both owned by GE Healthcare. Storm Phosphorimaging System and ImageQuant software (GE Healthcare, Pittsburgh, PA, USA). Percent methylation was determined using the formula: percent mC ¼ (C/(C þ T)) Â 100.
Epigenetic reactivation of CD133 was examined by treating sorted CD133À A2780 or PEO1 cells with 5 mM decitabine for 72 h, 300 nM trichostatin A (Sigma-Aldrich) for 24 h, or combined, with trichostatin A treatment from 48 to 72 h after the addition of decitabine. CD133 expression was analysed by flow cytometry as described above. Each experiment was performed in triplicate.
